Victoria Johnson

The approval was based on safety and efficacy data from 30 participants in 2 open-label, single-arm studies that received 1 to 3 infusions of donislecel.

All children included in the analysis with presymptomatic SMA achieved swallowing, oral nutrition, and airway protection outcomes.